Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Application based on results from the TROPION-Breast01 Phase III trial
The validations confirm the completion of the applications and commence the scientific review process
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Comprehensive clinical development programs being initiated for each investigational candidate
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
Subscribe To Our Newsletter & Stay Updated
